Rite Aid (RAD) Comps Up 2.9% in December
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Rite-Aid (RAD) December Results Positive Despite Flu-Relates Weakness in Scripts - Analyst Comments
January 3, 2014 10:20 AM ESTDeutsche Bank maintained a Buy rating on Rite-Aid (NYSE: RAD) with a price target of $7.00. For the four weeks ended Dec. 28, 2013, Rite-Aid same store sales increased 2.9 percent over the prior-year period. December front-end same store sales increased 1.0 percent. Pharmacy same store sales, which included an approximate 102 basis points negative impact from new generic... More
